CVXGA1 not checked
CyanVac LLC · PIV5-SARS CoV-2 vaccine
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Covid19
- Main trialPhase 1
- “This Phase 1 trial is an open-label trial to evaluate the safety, reactogenicity and immunogenicity of two dosages (10\^6 PFU and 10\^7 PFU) of intranasal CVXGA1 administered as a single dose in healthy adults age 18-55 years and in adolescents age 12-17.”In the company’s words, NCT04954287 on ClinicalTrials.gov
- Other names
- PIV5-SARS CoV-2 vaccine
Other drugs for Covid19
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 10 Jun 2023 | Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026